Related Experiment Videos

Analgesic efficacy of tramadol 2 mg kg(-1) for paediatric day-case adenoidectomy

H Viitanen1, P Annila

  • 1Department of Surgery and Anaesthesia, Central Hospital of Seinäjoki, Finland.

Insights

Tramadol effectively reduced the need for rescue analgesia in children aged 1-3 years after adenoidectomy. Significantly fewer children receiving tramadol required additional pain medication post-surgery.

Area of Science:

  • Pediatric Anesthesiology
  • Pain Management
  • Pharmacology

Background:

  • Post-operative pain management in children undergoing adenoidectomy is crucial for recovery.
  • Optimizing analgesia while minimizing adverse effects is a key clinical challenge.

Purpose of the Study:

  • To evaluate the analgesic efficacy of intravenous tramadol in young children (1-3 years) after day-case adenoidectomy.
  • To compare the need for rescue analgesia and recovery outcomes between tramadol and placebo groups.

Main Methods:

  • A randomized controlled trial involving 80 children aged 1-3 years undergoing adenoidectomy.
  • Children received either intravenous tramadol (2 mg/kg) or placebo post-induction of anesthesia.
  • Pain and recovery assessments were conducted by a blinded observer, with rescue medication administered as needed.

Main Results:

  • Children in the tramadol group required significantly fewer doses of rescue pethidine (P = 0.014).
  • Forty-five percent of children receiving tramadol did not require any post-operative analgesia, compared to 15% in the placebo group (P = 0.003).
  • Recovery times and adverse event incidence were similar between groups.

Conclusions:

  • Intravenous tramadol (2 mg/kg) provides effective post-operative analgesia in children aged 1-3 years after adenoidectomy.
  • Tramadol administration significantly reduces the need for supplementary analgesics without increasing adverse effects or delaying recovery.

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.